Deciphering Distinct Genetic Risk Factors for FTLD-TDP

Pathological Subtypes via Whole-Genome Sequencing

1

2

30

- 3 Cyril Pottier^{1,2,3,4,5,*}, Fahri Küçükali^{2,3}, Matt Baker¹, Anthony Batzler⁶, Gregory D. Jenkins⁶,
- 4 Marka van Blitterswijk¹, Cristina T. Vicente^{2,3}, Wouter De Coster^{2,3}, Sarah Wynants^{2,3}, Pieter
- 5 Van de Walle^{2,3}, Owen A. Ross¹, Melissa E. Murray¹, Júlia Faura^{2,3}, Stephen J. Haggarty⁷,
- 6 Jeroen GJ. van Rooij⁸, Merel O. Mol⁸, Ging-Yuek R. Hsiung⁹, Caroline Graff^{10,11}, Linn
- 7 Öijerstedt^{10,11}, Manuela Neumann^{12,13}, Yan Asmann¹⁴, Shannon K. McDonnell⁶, Saurabh
- 8 Baheti⁶, Keith A. Josephs¹⁵, Jennifer L. Whitwell¹⁶, Kevin F. Bieniek^{1,17}, Leah Forsberg¹⁵,
- 9 Hilary Heuer¹⁸, Argentina Lario Lago¹⁸, Ethan G. Geier¹⁸, Jennifer S. Yokoyama¹⁸, Alexis P.
- 10 Oddi¹⁸, Margaret Flanagan¹⁷, Qinwen Mao¹⁹, John R. Hodges²⁰, John B. Kwok^{21,22}, Kimiko
- 11 Domoto-Reilly²³, Matthis Synofzik^{12,24}, Carlo Wilke^{12,24}, Chiadi Onyike²⁵, Bradford C.
- 12 Dickerson²⁶, Bret M. Evers²⁷, Brittany N. Dugger²⁸, David G. Munoz^{29,30}, Julia Keith^{30,31},
- Lorne Zinman³¹, Ekaterina Rogaeva³², EunRan Suh³³, Tamar Gefen³⁴, Changiz Geula³⁴,
- Sandra Weintraub³⁴, Janine Diehl-Schmid^{35,36}, Martin R. Farlow³⁷, Dieter Edbauer³⁸, Bryan K.
- Woodruff³⁹, Richard J. Caselli³⁹, Laura L. Donker Kaat⁴⁰, Edward D. Huey⁴¹, Eric M.
- 16 Reiman⁴², Simon Mead⁴³, Andrew King^{44,45}, Sigrun Roeber⁴⁶, Alissa L. Nana¹⁸, Nilufer
- 17 Ertekin-Taner^{1,47}, David S. Knopman¹⁵, Ronald C. Petersen¹⁵, Leonard Petrucelli¹, Ryan J.
- 18 Uitti⁴⁷, Zbigniew K. Wszolek⁴⁷, Eliana Marisa Ramos⁴⁸, Lea T. Grinberg¹⁸, Maria Luisa Gorno
- 19 Tempini¹⁸, Howard J. Rosen⁴⁹, Salvatore Spina¹⁸, Olivier Piguet⁵⁰, Murray Grossman⁵¹, John
- 20 Q. Trojanowski³³, Dirk C. Keene⁵², Jin Lee-Way⁵³, Johannes Prudlo^{54,55}, Daniel H.
- 21 Geschwind⁴⁸, Robert A. Rissman⁵⁶, Carlos Cruchaga⁵⁷, Bernardino Ghetti⁵⁸, Glenda M.
- Halliday²¹, Thomas G. Beach⁵⁹, Geidy E. Serrano⁵⁹, Thomas Arzberger^{46,60}, Jochen Herms^{38,46},
- Adam L. Boxer¹⁸, Lawrence S. Honig⁶¹, Jean P. Vonsattel⁶², Oscar L. Lopez⁶³, Julia Kofler⁶⁴,
- 24 Charles L. White III²⁷, Marla Gearing⁶⁵, Jonathan Glass⁶⁵, Jonathan D. Rohrer⁶⁶, David J.
- 25 Irwin⁵¹, Edward B. Lee³³, Vivianna Van Deerlin³³, Rudolph Castellani⁶⁷, Marsel M.
- Mesulam³⁴, Maria C. Tartaglia³², Elizabeth C. Finger⁶⁸, Claire Troakes⁴⁴, Safa Al-Sarraj^{44,69},
- 27 Bruce L. Miller¹⁸, Harro Seelaar⁸, Neill R. Graff-Radford⁴⁷, Bradley F. Boeve¹⁵, Ian RA.
- Mackenzie⁷⁰, John C. van Swieten⁸, William W. Seeley¹⁸, Kristel Sleegers^{2,2}, Dennis W.
- 29 Dickson¹, Joanna M. Biernacka^{6,71}, Rosa Rademakers^{1,2,3,*}

31 † In memoriam

32

38

44

- * Corresponding Authors
- 33 Rosa Rademakers, Ph.D. (ORCID: 0000-0002-4049-0863)
- 34 VIB Center for Molecular Neurology
- 35 Universiteitsplein 1, 2610 Wilrijk, Belgium
- 36 Phone: +32 3 265 95 95
- 37 E-mail: <u>rosa.rademakers@uantwerpen.vib.be</u>
- 39 Cyril Pottier, Ph.D.
- 40 Department of Neurology, Washington University School of Medicine
- 41 St Louis, MO, United States of America
- 42 Phone: +1 314 747 2601
- 43 E-mail: cpottier@wustl.edu
- ¹Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224,
- 46 United States of America
- ²Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 48 ³VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- 49 ⁴Department of Neurology, Washington University School of Medicine, St Louis, MO,
- 50 United States of America
- ⁵NeuroGenomics and Informatics Center, Washington University School of Medicine, St
- 52 Louis, MO, United States of America
- ⁶Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, United
- 54 States of America
- ⁷Department of Neurology, Massachusetts General Hospital and Harvard Medical School,

- Boston, MA, 02114, United States of America
- 57 Bepartment of Neurology, Erasmus Medical Center, Wytemaweg 80, Rotterdam, 3015 CN,
- 58 The Netherlands
- ⁹Department of Medicine, Division of Neurology, University of British Columbia,
- 60 Vancouver, BC, V6T 2B5, Canada
- 61 ¹⁰Division of Neurogeriatrics, Karolinska Institutet, Bioclinicum J10:20, Visionsgatan 4,
- 62 Solna, 171 64, Sweden
- 63 ¹¹Unit for Hereditary Dementias, Karolinska University Hospital, Solna, 171 64, Sweden
- 64 ¹²German Center for Neurodegenerative Diseases (DZNE), Tübingen, 72076, Germany
- 65 ¹³Department of Neuropathology, University of Tübingen, Tübingen, 72076, Germany
- 66 ¹⁴Department of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville,
- 67 FL, 32224, United States of America
- 68 ¹⁵Department of Neurology, Mayo Clinic, Rochester, MN, 55905, United States of America
- 69 ¹⁶Department of Radiology, Mayo Clinic, Rochester, MN, 55905, United States of America
- 70 ¹⁷University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, United
- 71 States of America
- 72 ¹⁸Department of Neurology, UCSF Weill Institute for Neurosciences, University of
- 73 California, San Francisco, San Francisco, CA, 94158, United States of America
- 74 ¹⁹Department of Pathology, University of Utah, Salt Lake City, UT, 84112, United States of
- 75 America
- ²⁰Central Clinical School and Brain and Mind Centre, University of Sydney, Sydney, 2050,
- 77 Australia
- 78 ²¹University of Sydney, Sydney, 2050, Australia
- 79 ²²NeuRA, University of New South Wales, Randwick, 2031, Australia
- 80 ²³Department of Neurology, University of Washington, 325 9th Ave, Seattle, WA, 98104,
- 81 United States of America
- 82 ²⁴Division Translational Genomics of Neurodegenerative Diseases, Center for Neurology and
- 83 Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
- 84 ²⁵Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore,
- MD, 21218, United States of America
- 86 ²⁶Department of Neurology, Case Western Reserve University, Cleveland, OH, 44106,
- 87 United States of America
- 88 ²⁷Division of Neuropathology, University of Texas Southwestern Medical Center, 5323 Harry
- 89 Hines Blvd, Dallas, TX, 75390-9073, United States of America

- 90 ²⁸Department of Pathology and Laboratory Medicine, University of California, Davis
- 91 Medical Center, Sacramento, CA, 95817, United States of America
- 92 ²⁹St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B 1W8, Canada
- 93 ³⁰Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto,
- 94 ON, M5S 1A1, Canada
- 95 ³¹Sunnybrook Health Sciences Centre, Toronto, ON, M4N 3M5, Canada
- 96 ³²Krembil Discovery Tower, Tanz Centre for Research in Neurodegenerative Disease,
- 97 University of Toronto, 60 Leonard Av, Toronto, ON, M5T 0S8, Canada
- 98 ³³Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease
- 99 Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA,
- 100 19104, United States of America
- 101 ³⁴Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern
- 102 University, Chicago, IL, 60611, United States of America
- 103 ³⁵Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich,
- 104 80333, Germany
- 105 ³⁶kbo-Inn-Salzach-Klinikum, Clinical Center for Psychiatry, Psychotherapy, Psychosomatic
- Medicine, Geriatrics and Neurology, Wasserburg/Inn, 83512, Germany
- 107 ³⁷Department of Neurology, Indiana University School of Medicine, 355 West 16th Street,
- 108 Indianapolis, IN, 46202, United States of America
- 109 ³⁸German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Str 17, Munich,
- 110 81377, Germany
- 111 ³⁹Department of Neurology, Mayo Clinic, Scottsdale, AZ, 85259, United States of America
- ⁴⁰Department of Clinical Genetics, Erasmus Medical Center, Wytemaweg 80, Rotterdam,
- 113 3015 CN, The Netherlands
- ⁴¹Department of Psychiatry and Human Behavior, Brown Alpert Medical School, Brown
- 115 University, Providence, RI, 02912, United States of America
- ⁴²Banner Alzheimer's Institute, Phoenix, AZ, 85006, United States of America
- 117 ⁴³MRC Prion Unit at University College London, Institute of Prion Diseases, London, United
- 118 Kingdom
- 119 ⁴⁴Department of Basic and Clinical Neuroscience, London Neurodegenerative Diseases Brain
- Bank, Institute of Psychiatry, Psychology and Neuroscience, King's College London,
- 121 London, SE5 8AF, United Kingdom
- 122 ⁴⁵Department of Clinical Neuropathology, King's College Hospital NHS Foundation Trust,
- 123 London, SE5 9RS, United Kingdom

- 124 ⁴⁶Centre for Neuropathology and Prion Research, Ludwig-Maximilians-University of
- Munich, Feodor-Lynen-Straße 23, Munich, 81377, Germany
- 126 ⁴⁷Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224,
- 127 United States of America
- ⁴⁸Department of Neurology, David Geffen School of Medicine, University of California, Los
- 129 Angeles, Los Angeles, CA, 90095, United States of America
- 130 ⁴⁹Department of Pathology, UCSF Weill Institute for Neurosciences, University of
- 131 California, San Francisco, San Francisco, CA, 94158, United States of America
- 132 ⁵⁰School of Psychology and Brain and Mind Centre, University of Sydney, Sydney, 2050,
- 133 Australia
- 134 ⁵¹Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of
- Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States of
- 136 America
- 137 ⁵²University of Washington BioRepository and Integrated Neuropathology (BRaIN) lab,
- Harborview Medical Center, 325 9th Ave, Seattle, WA, 98104, United States of America
- 139 ⁵³M.I.N.D. Institute Laboratory, University of California, Davis Medical Center, 2805 50th
- 140 St, Sacramento, CA, 95817, United States of America
- 141 ⁵⁴German Center for Neurodegenerative Diseases (DZNE), Rostock, 18147, Germany
- 142 ⁵⁵Department of Neurology, Rostock University Medical Center, Rostock, 18147, Germany
- 143 ⁵⁶Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of
- 144 Southern California, San Diego, CA, USA
- 145 ⁵⁷Department of Psychiatry, Knight Alzheimer Disease Research Center, Washington
- 146 University School of Medicine, Saint Louis, MO, 63108, United States of America
- 147 ⁵⁸Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,
- 148 635 Barnhill Drive, Indianapolis, IN, 46202, United States of America
- 149 ⁵⁹Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ,
- 150 85351, United States of America
- 151 ⁶⁰Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-
- University of Munich, Munich, 81377, Germany
- 153 ⁶¹Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the
- 154 Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York,
- 155 NY, 10032, United States of America
- 156 ⁶²Department of Pathology, Taub Institute for Research on Alzheimer's Disease and the
- 157 Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York,

158 NY, 10032, United States of America ⁶³Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of 159 160 America ⁶⁴Department of Pathology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of 161 162 America 163 ⁶⁵Department of Pathology and Laboratory Medicine and Department of Neurology, Emory 164 University, Atlanta, GA, 30322, United States of America 165 ⁶⁶Department of Neurodegenerative Disease, Dementia Research Centre, University College 166 London Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom 167 ⁶⁷Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, 168 IL, 60611, United States of America 169 ⁶⁸Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, 170 University of Western Ontario, London, ON, N6A 2E2, Canada 171 ⁶⁹King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom ⁷⁰Department of Pathology and Laboratory Medicine, University of British Columbia, 172 173 Vancouver, BC, V6T 1Z7, Canada 174 ⁷¹Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, 55905, United 175 States of America 176 177 **Abstract** 178 Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 179 180 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci 181 identified. We report our comprehensive genome-wide association study as part of the 182 International FTLD-TDP Whole-Genome Sequencing Consortium, including 985 cases and 3,153 controls, and meta-analysis with the Dementia-seq cohort, compiled from 26 183 184 institutions/brain banks in the United States, Europe and Australia. We confirm UNC13A as the strongest overall FTLD-TDP risk factor and identify TNIP1 as a novel FTLD-TDP risk 185 186 factor. In subgroup analyses, we further identify for the first time genome-wide significant loci

specific to each of the three main FTLD-TDP pathological subtypes (A, B and C), as well as enrichment of risk loci in distinct tissues, brain regions, and neuronal subtypes, suggesting distinct disease aetiologies in each of the subtypes. Rare variant analysis confirmed *TBK1* and identified *VIPR1*, *RBPJL*, and *L3MBTL1* as novel subtype specific FTLD-TDP risk genes, further highlighting the role of innate and adaptive immunity and notch signalling pathway in FTLD-TDP, with potential diagnostic and novel therapeutic implications.

Main

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Introduction

Frontotemporal lobar degeneration (FTLD) is one of the leading causes of dementia in individuals younger than 65 years but can also affect individuals later in life. The predominant clinical presentations of FTLD are behavior and language dysfunction resulting in behavioral variant frontotemporal dementia (bvFTD)¹, semantic variant primary progressive aphasia (svPPA), or nonfluent variant primary progressive aphasia (nfvPPA)². The diagnosis of FTLD can be established with certainty only with neuropathologic postmortem examination and is characterized neuropathologically with significant atrophy of the frontal and temporal lobes and accumulation of abnormal neuronal and/or glial inclusions upon immunohistochemical analysis. FTLD-TDP, characterized by neuronal and cytoplasmic aggregates of the DNA and RNA-binding protein TDP-43, is one of the two main pathological subtypes (the other being FTLD-Tau) and can be further classified into five FTLD-TDP subtypes (FTLD-TDP A-E) based on the distribution of the neuronal cytoplasmic TDP-43-positive inclusions and dystrophic neurites in the cortical layers^{3,4}. In general, an accurate prediction of the underlying neuropathological FTLD subtype of individual patients constitutes a diagnostic challenge; however, a few clinicopathological correlations exist. Specifically, over 80% of patients clinically presenting with svPPA are diagnosed as FTLD-TDP C at autopsy⁵, and patients with bvFTD with concomitant amyotrophic lateral sclerosis (ALS) almost invariably present as FTLD-TDP B at autopsy^{2,4,6}. A small number of autosomal dominant genes and risk factors associated with FTLD-TDP have been reported⁷⁻¹³. The first FTLD-TDP genome-wide association study (GWAS) identified the TMEM106B locus (rs1990622), supporting lysosomal dysfunction in FTLD-TDP; however, this signal was strongly driven by GRN mutation carriers included in that study. Three

additional FTLD-TDP loci, *UNC13A*, *DPP6* and *HLA-DQA2*, were identified in phase I of the International FTLD-TDP whole-genome sequencing (WGS) consortium and require replication in larger datasets¹¹. Importantly, most FTLD-TDP patients are not yet genetically explained, and the relatively small sample size precluded rare variant analyses in phase I.

To replicate and identify new genetic risk factors, we doubled the original sample size of the FTLD-TDP WGS consortium by not only sequencing more pathologically confirmed FTLD-TDP cases but also including clinically defined FTLD subtypes enriched for specific FTLD-TDP pathological subtypes at autopsy. GWAS analyses of both common and rare variants, followed by comprehensive gene-prioritization, enrichment analyses, and co-localization studies identified novel FTLD-TDP risk loci, including novel risk genes and loci specific to FTLD-TDP pathological subtypes. Our study highlights similarities and differences between FTLD-TDP and other neurodegenerative diseases while unique biological processes in specific tissues, brain regions, and cell types were found to characterize individual FTLD-TDP pathological subtypes.

Results

GWAS analysis

Common variant genome-wide association study

To identify novel common FTLD-TDP genetic risk factors, we performed single variant GWAS using an additive disease risk model for 6,568,099 common variants in 985 patients and 3,153 controls free of neurodegenerative disorder that passed quality control (QC). Combining all patients (FTLD-TDP All) we identified one genome-wide significant signal at the *UNC13A* locus (rs8111424, OR=1.37, *P*=1.17x10⁻⁸). We also performed separate GWAS within the FTLD-TDP A, FTLD-TDP B, and FTLD-TDP C pathological subtypes (**Fig. 1**,

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Tables 1-2). The most significant locus identified in FTLD-TDP A was GRN (rs5848; OR=1.89, $P=5.57 \times 10^{-9}$). In phase I, this locus only reached genome-wide significance under an exploratory recessive model¹¹, and also now, the recessive model provided an even stronger association (OR=4.12, P=8.28x10⁻¹⁵). We further detected 3 additional new genome-wide significant loci in FTLD-TDP A: TINAG (rs138698596), MZT1 (rs138959102) and FARP2 (rs886815). In FTLD-TDP B, we detected a genome-wide significant association at the UNC13A locus (rs12973192). The lead variant rs12973192 is in linkage disequilibrium (LD) with rs8111424 (D'=1; r²=0.43) identified in the FTLD-TDP All analysis. We further detected 3 new genome-wide significant risk loci in FTLD-TDP B: TNIP1 (rs871269), RCL1 (rs7674221), PDS5B (rs5277499), and one in FTLD-TDP C C19orf52 (also known as TIMM29, rs576561313). In order to prioritize risk genes and identify possible biological mechanisms, we applied a range of variant annotation and molecular quantitative trait loci (QTL)-GWAS integration analyses as previously described¹⁴ (Supplementary Tables 2-13). We integrated different levels of evidence using a weighting scheme and obtained a weighted sum of the hits in different subcategories for each gene. We grouped candidate risk genes in genome-wide significant loci and in subthreshold loci and prioritized them at two levels of confidence for being a likely risk gene as tier 1 (higher confidence) and tier 2 (lower confidence). The gene prioritization analyses nominated a total of 59 tier 1 and 246 tier 2 genes in 258 different loci for 4 different GWAS analyses (Fig. 2, Supplementary Table 3, Supplementary Fig. 2-5). Our results showed that the nearest protein-coding genes were prioritized as tier 1 (n=8) and tier 2 (n=1) risk genes in the genome-wide significant loci for the distinct FTLD-TDP subtypes. Of the 8 tier 1 prioritized genes, 3 were found in common variant loci where molecular QTL-GWAS analyses aided their prioritization (Fig. 2). First, in locus A4, GRN was prioritized through consistent expression QTL (eQTL) domain hits in bulk

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

brain regions (eQTL Prosmap DLPFC=6.32x10⁻³⁸ and betarosmap DLPFC=-0.25, eQTL colocalization (coloc) PPH4s of 81.8%-99.7%, and fine-mapped [posterior inclusion probability being 100%] expression transcriptome wide association study [eTWAS] associations with P from 1.74×10^{-8} to 5.15×10^{-9} and Z-scores from -5.63 to -5.84) and in oligodendrocytes (cell type specific eQTL (ct-eQTL) coloc PPH4=90%) where genetic downregulation of GRN gene expression was associated with the FTLD-TDP A risk signal (Supplementary Tables 5, 6, and 11), which was also observed in brain proteome-wide association study (PWAS) with the same effect direction for the FTLD-TDP A risk (P_{ROSMAP} DLPFC = 3.32x10⁻⁶, Z_{ROSMAP DLPFC} = -4.65, **Supplementary Table 13**). Second, in locus B1, TNIP1 was prioritized because the minor allele was associated with decreased TNIP1 expression ($P_{ROSMAP DLPFC} = 2.40 \times 10^{-4}$, beta_{ROSMAP DLPFC} = -0.10), the GWAS signal colocalized with a microglia splicing QTL (sQTL) associated with TNIP1 chr5:151032383-151035002 known splice junction (color PPH4=82.2%) and because the methylation QTL (mQTL) variants for cg03340667, a CpG ~3.7 kb upstream of the transcription start site (TSS) of the canonical transcript of TNIP1, colocalized with the GWAS variants (coloc PPH4=70%) in dorsolateral prefrontal cortex (DLPFC) (Supplementary Tables 5, 7, and 8). Third, in locus B4, UNC13A was prioritized through an eQTL-GWAS colocalization in temporal cortex (coloc PPH4=81.82%, Supplementary Table 6). Furthermore, beyond genome-wide significant loci, we identified additional candidate prioritized risk genes in subthreshold regions through molecular QTL-GWAS coloc and TWAS analyses, one important example being TMEM106B as the prioritized risk gene in locus A_S14. The FTLD-TDP A GWAS signal near TMEM106B colocalized with eQTL variants regulating TMEM106B gene expression in bulk brain regions (eQTL coloc PPH4s=81.40% in MayoRNASeq temporal cortex and 89.66% in GTEx brain cortex, **Supplementary Table 6**). We also observed a significant eTWAS association in GTEx cortex ($P=4.13\times10^{-7}$, Z=-5.06), together with a significant PWAS hit ($P=2.01\times10^{-8}$,

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

Zscore=5.61) (Supplementary Tables 11, 13). Finally, a significant hit in splicing TWAS in cortex (sTWAS, $P=6.66 \times 10^{-7}$, Z=-4.97) predicted a decreased preference for the *TMEM106B* splice junction chr7:12224385-12229679 with the increased FTLD-TDP A GWAS risk, while we also observed methylation OTL (mOTL) coloc hits for two CpGs for TMEM106B (~500 bp upstream cg23422036 coloc PPH4=94.25% and intronic cg09613507 coloc PPH4=94.09%) (Supplementary Tables 12, 8). We summarized our gene prioritization results in Fig. 2 for the genome-wide significant loci and a selection of the suggestive loci (with genes having GWAS evidence of $P \le 5 \times 10^{-6}$ in 1 Mb extended regions), and full results are presented in Supplementary Tables 3-13 and Supplementary Fig. 2-5. Next, we performed gene ontology analyses on tier1 prioritized genes. The most significant term in the nominated genes in FTLD-TDP All was positive regulation of defense response to bacterium (P=3.21x10⁻⁵). Lysosomal function appeared to be strongly affected in FTLD-TDP A with several genes such as GRN and TMEM106B (lysosomal organization GO term, $P=4.12\times10^{-4}$) as well as cathepsin B (CTSB). We further detected enriched terms for retrograde transport in FTLD-TDP B (P=2.21x10⁻³) driven by DENND2A and VPS53 genes and for excitatory postsynaptic potential in FTLD-TDP C ($p=1.48\times10^{-3}$) driven by *DMPK* and *P2RX5* genes (Fig. 3, Supplementary Table 14). Importantly, except for lysosomal transport, no terms overlapped between subtypes of FTLD-TDP, suggesting mostly distinct genetic etiologies in the different FTLD-TDP groups. To further characterize genetic factors associated with FTLD-TDP, we performed gene-based analyses on common variants with $P < 10^{-5}$ using MAGMA. Analyses of FTLD-TDP All did not yield exome-wide significant loci; however, FTLD-TDP A showed exome-wide significant signals for the two genes located at the GRN locus (FAM171A2, ITGA2B) and for TMEM106B $(P=4.74\times10^{-7})$. The TMEM106B signal was driven by the rs10281425 variant (OR=0.54,

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

 $P=2.12\times10^{-7}$). No exome-wide significant signal was detected for the other two FTLD-TDP pathological subtypes. Expression of the top suggestive signals in cell types and brain regions To find tissues and cell types for which gene expression profiles were enriched for genes within FTLD-risk loci, we combined gene-based association statistics calculated using MAGMA with gene expression patterns from the Genotype–Tissue Expression (GTEx) project in a gene set enrichment analysis. We observed an enrichment in genes expressed in brain tissue (cerebellum, frontal cortex, and cortex) in FTLD-TDP A and B. This was strikingly different from the signature observed in FTLD-TDP C for which significant enrichment was only detected in non-central nervous system tissue, in particular small intestine terminal ileum (Fig. **4, Supplementary Table 15**). We also compared FTLD gene expression loci with similar data obtained from Alzheimer's disease and related disorders (ADRD)¹⁴ and ALS GWAS¹⁵. FTLD-TDP subtypes presented with a distinct genetic signature as compared to these related disorders highlighting the importance of regional specificity in FTLD-TDP. We subsequently queried PsychENCODE frontal-cortex single-cell RNA-seq datasets of human-derived brain samples to specify further which brain-specific enriched cell types express the genetic loci associated with FTLD-TDP risk (Fig. 4, Supplementary Table 16). We observed a significant enrichment in genes expressed in excitatory neurons for FTLD-TDP A loci (Ex4 $P=3.55 \times 10^{-2}$, Ex5b $P=2.72 \times 10^{-2}$), and FTLD-TDP B loci (Ex8 $P=1.27 \times 10^{-4}$), while no other cell type reached significance. While FTLD-TDP C loci were also significantly enriched in genes expressed in excitatory neurons (Ex3e $P=2.10 \times 10^{-2}$), they were additionally enriched in genes expressed in astrocytes and oligodendrocyte progenitor cells ($P=4.69 \times 10^{-2}$, $P=2.53\times10^{-2}$). Genes expressed in microglia were enriched only in ADRD gene loci $(P=1.90 \times 10^{-2})$. Overall, loci comprising genes expressed in excitatory neurons were enriched

342

343344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

in the three FTLD-TDP subtypes with stronger specificity for specific neuron types in each FTLD-TDP subtype as compared to what was observed for ALS gene loci. UNC13A and TNIP1 loci To provide further support for the identified FTLD-TDP risk loci, we performed a metaanalysis of our FTLD-TDP cohort with the Dementia-seq study (phs001963.v1.p1) that includes 2,102 clinical FTLD patients and 1,748 controls. Given that this cohort lacks details on the FTLD pathology underlying each patient, pathological subgroup analyses could not be performed. Meta-analysis confirmed UNC13A and identified the new TNIP1 locus as genomewide significantly associated with FTLD $(P_{rs12973192}=8.85\times10^{-10}; P_{rs871269}=3.42\times10^{-8},$ respectively). Note that the most significant single nucleotide variant (SNV) at the UNC13A locus was rs12608932 (p=9.13x10⁻¹¹), in strong LD with rs12973192 (r^2 =0.96 D'=0.99). Both UNC13A and TNIP1 were previously associated with other neurodegenerative diseases 14,16. Colocalization analyses showed that our UNC13A signal was shared with ALS (color PPH4=95.71%), strongly confirming the genetic overlap between both diseases (Fig. **5A**). Interestingly, for *TNIP1* we found strong colocalization with the ADRD association signal^{14,16} (coloc PPH4=99.2%) while its colocalization with ALS was weaker (71.5%), which was confirmed in a specificity analysis (color PPH4=20.1%, for p12=10e-06), possibly reflecting multiple independent association signals in FTLD in this locus (Fig. 5B-C). Rare variant analysis To identify genes carrying rare variants contributing to FTLD-TDP, we performed a burden test in genes with variants likely to affect protein function. In the overall FTLD-TDP cohort, no exome wide significant gene was detected (Supplementary Table 17). We did detect five exome-wide significant signals within FTLD-TDP pathological subtypes (Table 3, **Supplementary Table 18**). TBK1 was associated with disease status in FTLD-TDP A and B $(P=1.27\times10^{-11}, P=3.17\times10^{-12}, \text{ respectively})$. The signal was driven by 3 carriers in FTLD-TDP

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

A patients (3/193=1.5%) and 5 carriers in FTLD-TDP B patients (5/288=1.7%). We also detected an enrichment in rare variants in VIPR1 in FTLD-TDP B (P=4.65e-07, 3/288 FTLD-TDP B and 1/3153 control; Fig. 6) and 2 exome wide significant signals in FTLD-TDP C L3MBTL1 ($P=2.87 \times 10^{-7}$, 8/467 FTLD-TDP C and 3/3153 controls) and RBPJL ($P=6.39 \times 10^{-7}$, 5/467 FTLD-TDP C and 3/3153 controls). Weighted gene coexpression network analysis using the ROSMAP dataset and the BrainExp database¹⁷ revealed that L3MBTL1 and RBPJL module (yellow, $P_{L3MBTLI}=1.32\times10^{-45}$, $P_{RBPJL}=1.00\times10^{-79}$; belonged to the same Supplementary Figure 6) that is enriched in neuroactive ligand-receptor interaction and the cytokine-cytokine receptor interaction gene-ontology terms ($P_{\rm FDR}$ =3.7x10⁻¹², $P_{\rm FDR}$ =5.8x10⁻¹², respectively). While expression of L3MBTL1 was throughout the central nervous system cells, RBPJL expression was restricted to inhibitory neurons and in particular to Parvalbumin neurons (Supplementary Figure 6). **Discussion** In this work, we report 8 new genome-wide significant FTLD-TDP risk loci and 3 new genes harboring rare variants contributing to FTLD-TDP risk, by performing the largest FTLD-TDP WGS study to date, including 985 patients and 3,153 controls. A comprehensive analysis of our data highlights the genetic overlap between FTLD-TDP, ADRD, and ALS while also defining tissue and cell type enrichment unique to FTLD-TDP. Most importantly, we highlight distinct genetic aetiologies for each of the three main FTLD-TDP pathological subtypes (A, B and C) suggesting that multiple distinct pathomechanisms underlie the TDP-43 dysfunction and deposition in FTLD-TDP (Fig. 7). We confirm and replicate for the first time our previously reported GWAS signal at the UNC13A locus in FTLD-TDP patients¹¹. The UNC13A risk haplotype tagged by rs12973192 and rs12608932 was previously shown to increase cryptic splicing of UNC13A in brain tissue by modulating TDP-43 binding ^{18,19}. The cryptic splicing leads to transcripts with premature

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

stop codons and the subsequent loss of UNC13A protein, significantly impacting the release of vesicles in glutamatergic synapses²⁰. Since *UNC13A* thus represents a shared risk factor between ALS and FTLD-TDP additional genetic or environmental mechanisms likely drive disease presentation. We further establish and replicate a novel genetic association between the TNIP1 locus and FTLD-TDP. Recently, Restuadi et al. deeply characterized the GPX3/TNIP1 locus associated with ALS and suggested that GPX3 should be prioritized for deeper exploration into disease mechanisms related to this region²¹. GPX3, encoding for glutathione peroxidase 3, is a secreted enzyme involved in the regulation of oxidative damage, and its levels were found to be reduced in ALS sera²². Interestingly, however, the risk variant associated with FTLD-TDP (rs871269) is an expression quantitative trait locus for TNIP1 in the dorsolateral prefrontal cortex, and along with the fact that we only observed a weak colocalization signal with the ALS locus, we highlight TNIP1 as the most likely gene candidate for FTLD-TDP. In fact, we observed a shared signal at this locus between our FTLD-TDP GWAS and the recent large ADRD GWAS¹⁴, suggesting genetic and/or clinical overlap between AD and FTLD-TDP. TNIP1 is a ubiquitin-binding adaptor protein that regulates cell death and innate immune response through NF-kb activation²³⁻²⁵. TNIP1 undergoes phosphorylation by TBK1 and interacts with OPTN²⁶, two proteins associated with FTLD-TDP etiology^{12,27}. While this functional connection further supports TNIP1 as FTLD-TDP risk gene, more work is needed to understand the mechanisms underlying disease onset. Overall, we substantiate the genetic overlap between ALS, ADRD, and FTLD-TDP and emphasize the need for deeper exploration into pathways underlying disease-specific risk. One of the most striking conclusions from this phase II FTLD-TDP GWAS is the distinct association signals among FTLD-TDP pathological subtypes. Even the UNC13A and TNIP1 risk loci, which reach genome-wide significance in the meta-analysis stage, show stronger

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

association in FTLD-TDP B alone, and for the first time, genome-wide significant common risk loci are reported for each of the individual pathological FTLD-TDP subtypes. In FTLD-TDP A, in addition to individual genome-wide significant common variants assigned to GRN, TINAG, MZT1, and FARP2 risk loci, we identified exome-wide significant association with the burden of common variants in GRN and TMEM106B, in addition to multiple QTLbased analyses prioritizing TMEM106B as a tier 1 risk gene, re-enforcing the specific connection of these genes with FTLD-TDP A, even in patients without loss-of-function GRN mutations^{11,28}. While GRN and TMEM106B are also reported as AD risk genes¹⁴, an even stronger connection exists between these genes and limbic-predominant age-related TDP-43 encephalopathy (LATE)^{29,30}, which has a more restricted neuroanatomical distribution of TDP-43 pathology as compared to FTLD-TDP but with some characteristics of FTLD-TDP type A^{31,32}. The *TMEM106B* signal is primarily influenced by rs10281425, a variant located in the 3'UTR of TMEM106B, which tags the previously reported TMEM106B risk haplotype³³ associated with an increase in TMEM106B mRNA expression³³ and a higher burden of insoluble disease-associated TMEM106B C-terminal fragments³⁴. More broadly, also including prioritized genes from the subthreshold regions, gene ontology analysis in FTLD-TDP A revealed enrichment in genes implicated in lysosomal function driven by GRN, TMEM106B but also CSTB, three genes which also had the highest individual gene scores in the prioritization analysis in FTLD-TDP A. CSTB encodes one of the most abundant lysosomal proteases in the brain³⁵, and has been reported as a progranulin protease^{36,37}. Genes involved in lysosomal dysfunction were also overrepresented in FTLD-TDP B, including GRN and PPT1. PPT1, is a lysosomal enzyme which facilitates the degradation of fatty-acylated proteins by lysosomal hydrolases. Mutations in *PPT1* cause neuronal ceroid lipofuscinosis 1^{38,39} and *Ppt1* knock-out mice displayed fewer lipid droplets (LD) than wild type, indicating impairment of lipophagy, previously associated with FTLD/ALS⁴⁰⁻⁴³. Overall, our genetic data provides

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

compelling evidence that lysosomal dysfunction contributes to the pathobiology of FTLD-TDP A, and, to a lesser extent FTLD-TDP B. For FTLD-TDP B, additionally, we identified individual genome-wide significant associations with variants in the *RCL1* and *PDS5* loci, and we observed enrichment for gene ontology terms related to retrograde transport resulting from the VPS53 and DENND2A loci. VPS53 is part of the Golgi-associated retrograde protein (GARP) complex^{44,45} involved in intracellular cholesterol transport by targeting NPC2 to lysosomes⁴⁶. Recently, laser capture microdissection and single-cell mass spectrometry-based proteomics in motor neurons of ALS patients revealed a strong reduction in endolysosomal trafficking complexes such as the GARP complexes⁴⁷. Limited information about DENN2A function is currently available, but structural and functional analysis indicates it may be involved in intracellular vesicle trafficking to the lysosome and to the Golgi through its guanine nucleotide exchange factor activity and regulation of RAB family GTPases⁴⁸. However, retrograde transport has been previously implicated in ALS with, for instance, mutations in DCTN1^{49,50} and KIF5A^{51,52}, highlighting functional connections of prioritized genes from the subthreshold loci with TDP-43 dysfunction and ALS. Future GWAS with larger sample sizes, potentially combining FTLD-TDP B and ALS, are required to firmly establish a genetic contribution of this pathway to disease. Focusing on rare variants, exome-wide significant association with TBK1 was observed in both FTLD-TDP A and B (but not FTLD-TDP C), confirming TBK1 mutations as the most common cause of FTLD-TDP after GRN and C9orf72¹². We further unveiled rare predicted pathogenic variants associated with FTLD-TDP B within VIPR1, which encodes for the vasoactive intestinal peptide receptor 1. The variants are predicted to lead to an alteration of VIPR1 function, impairing the vasoactive intestinal peptide (VIP) biological pathway. Indeed, VIPR1 is activated upon binding by VIP, which exerts a neuroprotective effect mainly through glial

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

cells^{53,54} even though neurons also express VIPRs^{55,56}. Notably, VIP is also a key regulator of innate and adaptive immunity⁵⁷, making it an important therapeutic target for multiple neurodegenerative diseases. Altogether, our studies suggest that lysosome dysfunction and/or alterations in the innate and adaptive immune system are important contributors to both FTLD-TDP A and B risk, yet to varying degrees in each pathological subtype and with likely important variability in the contribution from each pathway among individual patients. FTLD-TDP C was previously recognized as a clinicopathological entity distinct from FTLD-TDP A and B⁵⁸, and our genetic studies support this notion showing no overlap in common or rare risk genes with the other FTLD-TDP types. Importantly, however, while often considered a sporadic FTLD subtype ^{13,59,60}, we implicate several genes and risk loci in FTLD-TDP C and uncover a potential role for mitochondrial membrane dysfunction and the notch signaling pathway. C19orf52 (TIMM29), which mediates the import and insertion of multi-pass transmembrane proteins into the mitochondrial inner membrane, was identified as the first genome-wide significant risk locus for FTLD-TDP C. Rare-variant burden analyses further associated rare predicted pathogenic variants in the RBPJL gene with FTLD-TDP C. RBPJL encodes for the recombination signal binding protein for immunoglobulin kappa J region like transcription factor. RBPJL is able to repress Notch target gene expression (Hey1, Hey2, HeyL and Notch3)⁶¹. As such, our findings align with a previous analysis of sub-genome-wide significant genes in clinical svPPA patients, enriched in FTLD-TDP C, which highlighted an overrepresentation of the Notch pathway⁶². Interestingly RBPJL and L3MBTL1, the second gene carrying rare predicted pathogenic variants in FTLD-TDP C, are part of the same coexpression module, suggesting that they are functionally related. Moreover, L3MBTL1, a histone methyl-lysine binding protein, is a key regulator of proteotoxicity associated with C9orf72 dipeptide repeats and mutant SOD163 and was found to be increased in spinal cord of ALS patients. Furthermore, reduction of L3MBTL1 expression in drosophila models with the

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

C9orf72-associated dipeptides poly(PR) or poly(GR) ameliorated the rough-eye phenotype⁶³, suggesting that loss of L3MBTL1 expression is beneficial. While no RNA samples were accessible from rare variant carriers, nonsense-mediated decay escape has been reported in other genes linked to ALS⁶⁴. It is thus possible that the L3MBTL1 variants lead to the generation of truncated proteins with toxic gain-of-function, but additional work is necessary to understand the disease etiology fully. When analyzed in sum, common variants associated with the different FTLD-TDP pathological subtypes appeared to be located in genes expressed in excitatory neurons in contrast to AD risk variants, which are enriched in microglia. Interestingly, glutamatergic transmission impairment has been reported in FTLD⁶⁵⁻⁶⁹ and voxel-based brain changes have been significantly associated with spatial distribution of mGluR5 in symptomatic C9orf72 and GRN carriers⁷⁰. Therefore, and in line with previously reported studies, our data suggest that neurons are the major players in disease etiology, as compared to what has been observed in ADRD. Interestingly, the distribution of risk loci was specific to the cerebellar hemisphere and the frontal-cortex for both FTLD-TDP A and B, as opposed to FTLD-TDP C where genes expressed in small intestine were enriched in risk loci. While the link between gut microbiome and FTLD remains limited⁷¹, our data suggest that the gut-brain axis might be of interest for future studies. In fact, emerging evidence also supports a role for the gut-brain axis in autoimmune diseases⁷², a group of disorders that were found to be enriched in svPPA patients⁷³. In prior studies, besides UNC13A, common variants in the HLA and DPP6 loci were reported to be associated with FTLD^{11,13}. The *HLA-DR5* locus was identified as associated with clinical FTLD but was not replicated in phase I of our International FTLD-TDP WGS Consortium. HLA-DQA2 and DPP6 loci were reported as overall FTLD-TDP risk loci in phase I¹¹ but were not replicated in the current study. The relative composition of patients with FTLD-TDP pathological subtypes in phase I and II (e.g., less FTLD-TDP A in phase II) and inclusion of clinically diagnosed individuals in phase II may have contributed to this; however, it is also possible that the increase in sample size reduced type I errors from phase I. Importantly, we did identify and replicate in two independent cohorts the UNC13A and TNIP1 loci associated with FTLD-TDP. Replication of the newly identified risk loci, each specific to distinct neuropathological FTLD-TDP subtypes, will require additional GWAS studies in the future. Obtaining sufficient samples will, however, be challenging, especially for FTLD-TDP A, which lacks a clear clinical correlate of the pathological phenotype. Functional characterization of the newly identified genes and loci may also provide mechanistic insight. In conclusion, we confirmed UNC13A and identified 8 new genetic loci, i.e. TNIP1, GRN, TINAG, MZT1, FARP2, RCL1, PDS5B, and C19orf52, and 3 new genes with rare variants associated with FTLD-TDP risk, i.e. VIPR1, RBPJL, and L3MBTL1. By enriching in neuropathologically confirmed patients and substantially increasing our cohort size, we gained important knowledge in our understanding of FTLD-TDP pathophysiology. The recognition that individual FTLD-TDP subtypes could in fact be considered separate diseases with distinct pathomechanisms has significant implications for the design of clinical trials and therapeutic interventions.

Methods

Samples

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534535

536

537

538

539

540

Our current dataset includes previously generated data through the International FTLD-TDP WGS consortium phase I¹¹ with 554 persons with clinicopathologically defined FTLD-TDP and newly generated phase II sequencing data from 32 FTLD-TDP A, 43 FTLD-TDP B, 66 FTLD-TDP C, 4 FTLD-TDP E, and 9 with unclassifiable FTLD-TDP pathology (abbreviated as FTLD-TDP U, **Supplementary Table 19**). To increase statistical power, we also sequenced 70 persons with clinical diagnosis of bvFTD/ALS, a clinical subtype associated with FTLD-

TDP B, and 283 persons with svPPA, a clinical subtype associated with FTLD-TDP C. Overall, the total cohort pre-quality control was a combined FTLD-TDP cohort of 202 FTLD-TDP A, 237 FTLD-TDP B, 225 FTLD-TDP C, 4 FTLD-TDP D, 11 FTLD-TDP E, 29 FTLD-TDP U persons, 70 persons with bvFTD/ALS and 283 persons with svPPA. All persons clinically or pathologically diagnosed with FTLD are referred to as patients throughout the manuscript. We further used WGS data from 982 participants from the Mayo Clinic Biobank (from phase I)^{11,74}, 322 new controls free of neurodegenerative disorder from Mayo Clinic with WGS available, and 2,037 controls derived from the Alzheimer's disease sequencing project (ADSP). *C9orf72* repeat expansions were assessed in all patients using our previously reported two-step protocol and Sanger sequencing was used to perform mutation analyses of *GRN*^{7,9}. Patients with *C9orf72* repeat expansion and LOF mutations in *GRN* were removed prior to WGS. Study protocols were reviewed and approved by the appropriate institutional review boards.

Whole genome sequencing

In phase I of the International FTD-TDP WGS consortium, WGS was generated on 554 patients with FTLD-TDP (512 passed QC in that study)¹¹. Briefly, whole blood- or brain-derived DNA from 499 unrelated FTLD-TDP patients and 982 participants from the Mayo Clinic Biobank Study were sequenced at HudsonAlpha using the standard library preparation protocol using NEBNext® DNA Library Prep Master Mix Set for Illumina® (New England BioLabs Inc., Ipswich, MA, USA), Concentration of the libraries was assessed by Qubit® 2.0 Fluorometer, and the quality of the libraries was estimated by a DNA 5 K chip on a Caliper GX. Accurate quantification was determined using the qPCR-based KAPA Biosystems Library Quantification kit (Kapa Biosystems, Inc., Woburn, MA, USA). Each sample was sequenced on one lane of Illumina's HiSeq X instrument using v2 flow cells and reagents to target 30× genomic coverage. Fastq files previously generated on an Illumina HiSeq X for 55 FTLD-TDP patients were obtained from 3 sites: UCSF (n = 36), DZNE (n = 14) and NSW (n = 5). In phase

II, additional WGS of 507 patients with FTLD-TDP, svPPA, bvFTD/ALS and 322 controls free of neurodegenerative disorders was performed at USUHS sequencing center or Mayo Clinic Rochester using the TruSeq DNA PCR-Free Library preparation Kit (Illumina) followed by Whole Genome Sequencing by synthesis (SBS) chemistry on HiSeq X Illumina platform using the HiSeq X Ten Reag. kit v2.5. For all patients and controls, fastq files were transferred to Mayo Clinic and processed through the Mayo Genome GPS v4.0 pipeline in batches of up to 75 samples. Briefly, reads were mapped to the human reference sequence (GRCh38 build) using the Burrows—Wheeler Aligner, and local realignment around indels was performed using the Genome Analysis Toolkit (GATK). Variant calling was performed using GATK HaplotypeCaller followed by variant recalibration (VQSR) according to the GATK best practice recommendations. At the time of analysis, participants from the Mayo Clinic Biobank with possible clinical diagnosis or family history of a neurodegenerative disorder were removed. We also included genotypic data (vcf) from 2,037 controls from the Alzheimer's Disease Sequencing Project, leading to a total of 1,061 patients and 3,341 controls.

Sample level quality control and definition of subgroups

Samples with less than $30 \times$ coverage in more than 50% of the genome, call rate below 85%, sex error, contamination defined by a FREEMIX score above 4 or non-Caucasian ethnicity were removed. At this step, joint genotyping on all samples was performed, a final relatedness measurement was calculated using PREST⁷⁵, and duplicates were removed, while only one individual per family was kept. In total, 985 pathologically confirmed FTLD-TDP or presumed FTLD-TDP patients clinically presenting with svPPA or bvFTD/ALS, as well as 3,153 neurologically normal controls passed all quality control measures (**Supplementary Table 1**). Age at onset of svPPA and bvFTD/ALS did not differ from the age at onset of FTLD-TDP C (P=1) and FTLD-TDP B patients (P=1), respectively. Based on these findings and the previously established associations between the svPPA and bvFTD/ALS clinical diagnoses

with specific FTLD-TDP pathological subtypes, we combined svPPA with FTLD-TDP C and bvFTD/ALS with FTLD-TDP B patients in all analyses. Within our overall cohort of 193 FTLD-TDP A, 288 FTLD-TDP B (defined as FTLD-TDP B and bvFTD/ALS) and 467 FTLD-TDP C (defined as FTLD-TDP C and svPPA), the ages at onset and death differed significantly between the pathological FTLD-TDP subtypes (**Table 2**; **Supplementary Figure 1**). FTLD-TDP A patients had a later age at onset than FTLD-TDP B and FTLD-TDP C groups (*P*=4.73x10⁻⁸, *P*=1.37x10⁻¹³, respectively), and a later age at death (*P*=4.00x10⁻¹⁵, *P*=3.00x10⁻⁶, respectively). FTLD-TDP B had an earlier age at death as compared to FTLD-TDP C (*P*=5.60x10⁻⁸). Differences in age distribution in between patient groups were assessed using the Kruskal-Wallis test followed by Wilcoxon test correcting for multiple testing. Corrected *P* are provided.

Variant level quality control

591

592

593

594

595

596

597

598

599

600

601

602603

604

605

606

607

608

609

610

611

612

613

614

615

Genotype calls with genotype quality (GQ) < 20 and/or depth (DP) < 10 were set to missing, and variants with edit-distance > 4 and call rate < 80% were removed from all subsequent analyses leading to a total of 85,345,466 variants. For all analyses, only variants that pass VQSR (127,658 variants removed) and with a call rate > 95% in cases or controls were considered (591,431 variants removed). Functional annotation of variants was performed using ANNOVAR (version2016Feb01). Rare loss of function variants (frameshift insertion/deletion/block substitution, stopgain, stoploss and splicing single nucleotide variants—SNVs) identified in exome-wide significant associated genes in the rare variant analyses (Supplementary Table 17) were confirmed in patients by Sanger sequencing (primers available upon request). For the known neurodegenerative disease genes (GRN, MAPT, TBK1, OPTN, VCP, TARDBP, CHCHD10, SQSTM1, UBQLN2, hnRNPA1, hnRNPA2B1, CSF1R, FUS, CHMP2B, and LRRK2), potentially pathogenic rare variants were also identified and confirmed by Sanger sequencing (n=25; Supplementary Table 20).

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

Generation of principal components Prior to running genetic association analyses, principal component (PC) analysis was performed using a subset of variants meeting the following criteria: minor allele frequency (MAF)>5% and full sample Hardy-Weinberg Equilibrium (HWE) P>1x10⁻⁵. Influential regions such as the HLA region were removed, and variants were pruned by linkage disequilibrium with r² threshold of 0.1 prior to PC analysis. This analysis identified 13 PCs that were significantly associated with patient/control status, which were subsequently used as covariates in all genetic association analyses. Variant-level analysis of common variants For the common variant GWAS, single nucleotide variants (SNV) with MAF>0.01 in patients or controls (n=7,178,250 variants) and HWE $P>1.00x10^{-6}$ in controls were analyzed (17,450 variants removed). In addition, since whole genome sequencing of FTLD-TDP patients and controls was performed at multiple sites, a test was performed to identify variants with significant differences in genotype distributions between sequencing batches, and 592,701 SNVs showing evidence of batch effects (p < 0.05) were removed leading to a total of 6,568,099 variants analyzed. For all remaining variants, association of genotypes with the patient/control status was assessed using logistic regression with allele dosage as the predictor assuming log-additive allele effects. Sex and the first thirteen PCs were included as covariates in the models. The SNV-level analyses were performed using PLINKv.00a23LM2 combining all FTLD-TDP cases (FTLD-TDP All) and in FTLD-TDP pathological subtypes. Meta-analyses of FTLD-TDP phase II with publicly available dataset from the Dementia-seq project (phs001963.v2.p1) was performed under a fixed-effects model comparing our data with 2,102 FTLD cases and 1,748 controls from the Dementia-seq project using Metal⁷⁶. Dementia-seq vcf were processed the exact same

641

642643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

way as our data except that 10 PCs were included in the model to perform common variant association analysis. **Colocalization analyses** We performed colocalization analysis for *UNC13A* and *TNIP1* loci (top SNVs ± 100 kb) with ALS (GCST90027164) and ADRD (GCST90027158) using the 'coloc' package version 4.0.4 in R using our meta-analyses data. When the summary statistics of the other trait was expressed on another build than GRCh38, the variant alleles and positions were converted. We set the prior probabilities to $\pi 1 = 1 \times 10^{-4}$, $\pi 2 = 1 \times 10^{-4}$ and $\pi 12 = 1 \times 10^{-5}$ for a causal variant in trait 1 or trait 2 and a shared causal variant between traits 1 and 2, respectively (default parameters). Sensitivity analysis was performed at $\pi 12=1\times 10^{-6}$. P < 0.05 was considered statistically significant. Tissue and cell type enrichment analysis Tissue and cell type enrichment analyses were performed using the summary statistics and FUMA. Briefly, FUMA aggregates summary statistics per gene to calculate gene-wise association signals using MAGMA version 1.6 and subsequently tests whether tissues and cell types are enriched for expression of these genes. For tissue enrichment analysis, we used the GTEx version 8 reference set. P < 0.05 across all tissues (n = 54) were considered statistically significant. For cell type enrichment analyses, we used human-derived single-cell RNA-seq data from major brain cell types (PsychENCODE). Excitatory and inhibitory neurons from the PsychENCODE dataset were labeled based on their transcriptional profile from 1 to 8⁷⁷. *P*<0.05 were considered statistically significant. Gene prioritization and functional interpretation of GWAS We performed the gene prioritization and functional interpretation analyses for FTLD-TDP All and each FTLD-TDP pathological subtype separately by using the subtype-specific GWAS summary statistics. We adapted a systematic gene prioritization and functional interpretation

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

strategy (as previously described in Bellenguez et al. 14) to prioritize GWAS-implicated candidate risk genes and nominate possible downstream biological mechanisms. Briefly, six distinct domains, that are related to lead variant annotation and molecular QTL-GWAS integration analyses (e.g., colocalization and TWAS) in FTLD-relevant tissues and cell types were systematically assessed: (1) variant annotation, (2) eQTL-GWAS integration, (3) sQTL-GWAS integration, (4) protein expression QTL (pQTL)-GWAS integration, (5) mQTL-GWAS integration, and (6) histone acetylation QTL (haQTL)-GWAS integration; for which detailed information on categories and subcategories is provided in **Supplementary Table 2.** In the variant annotation domain, for each lead variant at each locus, we queried which candidate risk genes were the nearest protein-coding genes with respect to the genomic position of the lead variants, and/or whether the lead variant was a rare (MAF < 1% in gnomAD v4 non-Finnish European samples) and/or protein-altering (missense or predicted LOF) variant for the same nearest protein-coding genes. In the molecular QTL-GWAS integration domains, we leveraged molecular cis-QTL catalogues for different molecular phenotypes (i.e., gene expression, splicing, protein expression, methylation, and histone acetylation) in FTLDrelevant tissues and cell types, we performed genetic colocalization analyses between molecular cis-QTL and GWAS signals, TWAS, and proteome-wide association studies (PWAS). For these analyses, we processed and used publicly available molecular QTL catalogues; namely, FTLD-relevant bulk brain regions from AMP-AD⁷⁸⁻⁸¹ (as reanalyzed in Bellenguez et al.¹⁴) and GTEx v8⁸² cohorts for the bulk brain eQTLs and sQTLs, eight major brain cell types (excitatory neurons, inhibitory neurons, astrocytes, oligodendrocytes, microglia, oligodendrocyte precursor cells/committed oligodendrocyte precursors [OPCs/COPs], pericytes, and endothelial cells) from Bryois et al.⁸³ and primary microglia from Young et al. 84 and the MiGA study 85 for the brain cell-type-specific eQTLs (ct-eQTL) and for microglia sQTLs (from the MiGA study), dorsolateral prefrontal cortex (DLPFC) pQTLs from

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

Wingo et al. 86 (v2), and DLPFC mQTLs and haQTLs from Brain xQTL serve (June 2021 release)86,87. Finally, we also included naïve state monocyte and macrophage eQTL catalogues⁸⁸⁻⁹³ reanalyzed by eQTL Catalogue (Release 6)⁹⁴ and lymphoblastoid cell line (LCL) eOTLs from GTEx v8⁸² and the European Alzheimer & Dementia Biobank (EADB) Belgian LCL cohorts¹⁴. Using each of these molecular QTL catalogues, we first investigated whether the reported lead variants in this study were significant molecular QTLs for the quantified levels of molecular phenotypes in tissues and cell types of interest. Moreover, for each quantified molecular phenotype in these catalogues we performed molecular QTL-GWAS coloc (v5.2.2) analyses to determine if specific molecular QTL signals are colocalized (at coloc PP4 ≥ 70%) with FTLD subtype GWAS signals. Finally, we conducted TWAS (using FUSION and S-PrediXcan [implemented in MetaXcan] tools) for each heritable feature modelled in gene expression (eTWAS; followed by eTWAS fine mapping with FOCUS⁹⁵ [v0.803] within 1 Mb extended genome-wide significant lead variant genetic regions in each FTLD-TDP subtype GWAS), splicing (sTWAS), and PWAS reference panels derived from AMP-AD bulk brain⁷⁸-81, GTEx bulk brain and LCL⁸², EADB Belgian LCL¹⁴, and Wingo et al. DLPFC data⁸⁶, to identify the significant associations (after Bonferroni correction) between predicted levels of gene expression, splicing, and protein expression with each FTLD subtype-specific genetic risk. Detailed description and details (e.g., number of samples, significance criteria, references and sources) of these molecular QTL catalogues used in this study for the systematic gene prioritization strategy and functional interpretation of FTLD-TDP GWAS results can be found in Supplementary Table 5. Using a predetermined weighting scheme for each type of evidence (see **Supplementary Table** 3), we computed a gene prioritization score (between 0 and 87) for each gene which was constructed by the weighted sum of the hits in different subcategories within six distinct domains described above. As described in Bellenguez et al. 14 in detail, we gave higher weights for the hits obtained through the brain QTLs rather than other tissue QTLs, for the replicated hits across multiple catalogues or reference panels, and for the fine-mapped eTWAS hits. After obtaining weighted gene prioritization scores in each FTLD-TDP subtype-specific gene prioritization analysis, we first assigned each candidate risk gene (with gene prioritization score >0) to the genome-wide significant loci if their gene coordinates (based on GENCODE v24) are positioned within a ± 1 Mb window of the identified lead variants (**Table 2**). The rest of the candidate risk genes in subthreshold regions (nominated by coloc and TWAS analyses only) were grouped together if they were positioned together (<1 Mb), and these subthreshold regions were indexed and named as subthreshold loci. The candidate risk genes in genome-wide significant and subthreshold loci were also annotated by the evidence of minimum P observed within 1 Mb of the gene coordinates in related FTLD-TDP subtype-specific GWAS summary statistics. We then ranked the protein-coding genes per locus in each FTLD subtype-specific analysis based on their total weighted scores, and investigated the relative score differences between the highest ranked protein-coding gene and the other candidate risk genes in each locus, together with the overall total weighted score of the top-ranked gene. We then classified candidate risk genes in each locus as tier 1 and tier 2 prioritized risk genes, respectively having a higher and lower level of confidence for being a true risk gene in a given locus (see Bellenguez et al. 14 for detailed description). As also described in Bellenguez et al. 14, the gene prioritization pipeline determines a single tier 1 prioritized risk gene in each locus if there is adequate evidence, meanwhile additional tier 2 prioritized risk genes in the same loci or multiple tier 2 prioritized risk genes in a locus can also be assigned based on the score distribution of candidate genes in the investigated loci.

Gene Ontology analyses

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

739

Gene ontology on tier 1 genes identified in FTLD-TDP All or in individuals FTLD-TDP

subtype analyses were performed using anRichment R package which aggregates summary

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

statistics and assesses gene ontology term enrichment. Gene ontology terms were collapsed using the rrvigo R package. Only terms with 2 or more genes were considered in the analyses. P < 0.05 was considered statistically significant. **Gene-level analysis of rare variants** Association of rare variants with the patient/control status was assessed using an unweighted burden test implemented using the SKAT_1.2.1 R package. Only VQSR pass variants with call rate > 90%, ED ≤ 4 , and MAF < 0.01 in either patients or controls were included. We included only frameshift (insertion/deletion/block substitution), stopgain, stoploss and splicing SNVs (jointly defined as loss-of-function (LOF) variants), and non-synonymous SNVs with REVEL score above 0.75%. Sex and the first thirteen PCs were used as covariates. Genome-wide significance was defined as $P < 5 \times 10^{-8}$ and exome-wide significance as a p value $< 2.5 \times 10^{-6}$ (Bonferroni correction for 20,000 genes). RBPJL and L3MBTL1 RNA expression Assessment of module membership of RBPJL and L3MBTL1 was performed using the gene co-expression analysis from the BrainEXP-NPD¹⁷ website using default parameters. Single nuclei RNA expression was assessed using the transcriptomic comparative viewer if the Seattle Alzheimer's Disease Brain cell Atlas from middle temporal gyrus of 84 aged donors (42 cognitively normal and 42 with dementia). **Data Availability** Summary statistics will be available on dbGAP platform post publication. Datasets and molecular QTLs used in the gene prioritization are publicly available (see also **Supplementary Table 4):**

762 eQTLs and eTWAS reference panels in AD-relevant bulk brain regions from AMP-AD 763 cohorts and in LCLs from the EADB Belgian cohort, as analyzed by Bellenguez et al.¹⁴: https://doi.org/10.5281/zenodo.5745927; 764 765 sQTLs and sTWAS reference panels in AD-relevant bulk brain regions from AMP-AD cohorts and in LCLs from the EADB Belgian cohort, as analyzed by Bellenguez et 766 al¹⁴.: https://doi.org/10.5281/zenodo.5745929; 767 768 Bryois et al.⁸³ ct-eQTL catalogues (https://doi.org/10.5281/zenodo.5543734); 769 eQTL Catalogue database (https://www.ebi.ac.uk/eqtl/); 770 Brain xQTL serve mQTL and haQTL catalogues 771 (https://mostafavilab.stat.ubc.ca/xqtl/xQTL_updated_data/); 772 GTEx v8 eQTL and sQTL catalogues (https://www.gtexportal.org/); 773 GTEx v8 expression and splicing prediction models for eTWAS/sTWAS 774 (https://predictdb.org/post/2021/07/21/gtex-v8-models-on-eqtl-and-sqtl/#mashr-based-775 models); 776 MiGA eQTLs (https://doi.org/10.5281/zenodo.4118605); 777 MiGA sQTLs (https://doi.org/10.5281/zenodo.4118403); 778 MiGA meta-analysis (https://doi.org/10.5281/zenodo.4118676); and

Wingo et al. 86 pOTLs v2 (https://www.synapse.org/#!Synapse:syn23627957).

779

780

References

781

- 782 1. Rascovsky, K. *et al.* Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* **134**, 2456-77 (2011).
- 784 2. Gorno-Tempini, M.L. *et al.* Classification of primary progressive aphasia and its variants. *Neurology* **76**, 1006-14 (2011).
- 786 3. Lee, E.B. *et al.* Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. *Acta Neuropathol* **134**, 65-78 (2017).
- 789 4. Mackenzie, I.R. *et al.* A harmonized classification system for FTLD-TDP pathology. *Acta Neuropathol* **122**, 111-3 (2011).
- 791 5. Mackenzie, I.R. *et al.* Heterogeneity of ubiquitin pathology in frontotemporal lobar 792 degeneration: classification and relation to clinical phenotype. *Acta Neuropathol* **112**, 793 539-49 (2006).
- 794 6. Mackenzie, I.R. & Neumann, M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. *Acta Neuropathol* **134**, 79-96 (2017).
- 796 7. Baker, M. *et al.* Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* **442**, 916-9 (2006).
- 798 8. Cruts, M. *et al.* Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* **442**, 920-4 (2006).
- 9. DeJesus-Hernandez, M. *et al.* Expanded GGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* **72**, 245-56 (2011).
- 803 10. Renton, A.E. *et al.* A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* **72**, 257-68 (2011).
- Pottier, C. *et al.* Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. *Acta Neuropathol* **137**, 879-899 (2019).
- 808 12. Pottier, C. *et al.* Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. 810 *Acta Neuropathol* **130**, 77-92 (2015).
- Ferrari, R. *et al.* Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurol* **13**, 686-99 (2014).
- Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet* **54**, 412-436 (2022).
- Project Min, E.A.L.S.S.C. Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. *Eur J Hum Genet* **26**, 1537-1546 (2018).
- 818 16. Benyamin, B. *et al.* Cross-ethnic meta-analysis identifies association of the GPX3-819 TNIP1 locus with amyotrophic lateral sclerosis. *Nat Commun* **8**, 611 (2017).
- Jiao, C. *et al.* BrainEXP: a database featuring with spatiotemporal expression
 variations and co-expression organizations in human brains. *Bioinformatics* 35, 172-174 (2019).
- Brown, A.L. *et al.* TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. *Nature* **603**, 131-137 (2022).
- Ma, X.R. *et al.* TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. *Nature* **603**, 124-130 (2022).
- Augustin, I., Rosenmund, C., Sudhof, T.C. & Brose, N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. *Nature* **400**, 457-61 (1999).

- Restuadi, R. *et al.* Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. *Genome Med* **14**, 7 (2022).
- Tanaka, H. *et al.* ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis. *J Neurol* **260**, 1782-97 (2013).
- Oshima, S. *et al.* ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development. *Nature* **457**, 906-9 (2009).
- Su, Z. *et al.* ABIN-1 heterozygosity sensitizes to innate immune response in both RIPK1-dependent and RIPK1-independent manner. *Cell Death Differ* **26**, 1077-1088 (2019).
- Zhou, J. *et al.* A20-binding inhibitor of NF-kappaB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein beta activation and protects from inflammatory disease. *Proc Natl Acad Sci U S A* **108**, E998-1006 (2011).
- 26. Lee, Y. *et al.* Coordinate regulation of the senescent state by selective autophagy. *Dev Cell* **56**, 1512-1525 e7 (2021).
- Freischmidt, A. *et al.* Haploinsufficiency of TBK1 causes familial ALS and frontotemporal dementia. *Nat Neurosci* **18**, 631-6 (2015).
- Mackenzie, I.R. *et al.* The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. *Brain* **129**, 3081-90 (2006).
- 847 29. Katsumata, Y. *et al.* Multiple gene variants linked to Alzheimer's-type clinical dementia via GWAS are also associated with non-Alzheimer's neuropathologic entities. *Neurobiol Dis* **174**, 105880 (2022).
- 850 30. Katsumata, Y., Nelson, P.T., Ellingson, S.R. & Fardo, D.W. Gene-based association 851 study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, 852 TMEM106B, ABCC9, and KCNMB2. *Neurobiol Aging* **53**, 193 e17-193 e25 (2017).
- Nelson, P.T. *et al.* Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. *Brain* **142**, 1503-1527 (2019).
- Josephs, K.A. *et al.* Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. *Acta Neuropathol* **137**, 227-238 (2019).
- Van Deerlin, V.M. *et al.* Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat Genet* **42**, 234-9 (2010).
- 34. C, T.V. *et al.* C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes. *Brain* **146**, 4055-4064 (2023).
- Hook, V. *et al.* Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders. *Biochim Biophys Acta Proteins Proteom* **1868**, 140428 (2020).
- 865 36. Lee, C.W. *et al.* The lysosomal protein cathepsin L is a progranulin protease. *Mol Neurodegener* **12**, 55 (2017).
- 37. Zhou, X. *et al.* Lysosomal processing of progranulin. *Mol Neurodegener* **12**, 62 (2017).
- Vesa, J. *et al.* Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. *Nature* **376**, 584-7 (1995).
- 871 39. Camp, L.A., Verkruyse, L.A., Afendis, S.J., Slaughter, C.A. & Hofmann, S.L.
- Molecular cloning and expression of palmitoyl-protein thioesterase. *J Biol Chem* **269**, 23212-9 (1994).
- Branchu, J. *et al.* Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration. *Neurobiol Dis* **102**, 21-37 (2017).
- Han, S.M. et al. VAPB/ALS8 MSP ligands regulate striated muscle energy
- metabolism critical for adult survival in caenorhabditis elegans. *PLoS Genet* **9**, e1003738 (2013).

- Cingolani, F. & Czaja, M.J. Regulation and Functions of Autophagic Lipolysis.
 Trends Endocrinol Metab 27, 696-705 (2016).
- 43. Liu, Y. *et al.* A C9orf72-CARM1 axis regulates lipid metabolism under glucose starvation-induced nutrient stress. *Genes Dev* **32**, 1380-1397 (2018).
- Conibear, E. & Stevens, T.H. Vps52p, Vps53p, and Vps54p form a novel multisubunit complex required for protein sorting at the yeast late Golgi. *Mol Biol Cell* **11**, 305-23 (2000).
- Liewen, H. *et al.* Characterization of the human GARP (Golgi associated retrograde protein) complex. *Exp Cell Res* **306**, 24-34 (2005).
- Wei, J. *et al.* The GARP Complex Is Involved in Intracellular Cholesterol Transport via Targeting NPC2 to Lysosomes. *Cell Rep* **19**, 2823-2835 (2017).
- 890 47. Guise, A.J. *et al.* TDP-43-stratified single-cell proteomic profiling of postmortem 891 human spinal motor neurons reveals protein dynamics in amyotrophic lateral 892 sclerosis. *bioRxiv* (2023).
- 48. Yoshimura, S., Gerondopoulos, A., Linford, A., Rigden, D.J. & Barr, F.A. Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. *J Cell Biol* **191**, 367-81 (2010).
- 49. Deshimaru, M. *et al.* DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation.
 897 *Int J Mol Sci* 22(2021).
- 898 50. He, J., Yu, W., Liu, X. & Fan, D. An identical DCTN1 mutation in two Chinese 899 siblings manifest as dHMN and ALS respectively: a case report. *Amyotroph Lateral* 900 *Scler Frontotemporal Degener* **23**, 149-153 (2022).
- 901 51. Nicolas, A. *et al.* Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. *Neuron* **97**, 1267-1288 (2018).
- 903 52. Xia, C.H. *et al.* Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. *J Cell Biol* **161**, 55-66 (2003).
- 905 53. Brenneman, D.E., Hauser, J., Spong, C.Y. & Phillips, T.M. Chemokines released 906 from astroglia by vasoactive intestinal peptide. Mechanism of neuroprotection from 907 HIV envelope protein toxicity. *Ann NY Acad Sci* **921**, 109-14 (2000).
- 908 54. Brenneman, D.E. *et al.* Vasoactive intestinal peptide. Link between electrical activity and glia-mediated neurotrophism. *Ann N Y Acad Sci* **897**, 17-26 (1999).
- 910 55. Chneiweiss, H., Glowinski, J. & Premont, J. Vasoactive intestinal polypeptide 911 receptors linked to an adenylate cyclase, and their relationship with biogenic amine-912 and somatostatin-sensitive adenylate cyclases on central neuronal and glial cells in 913 primary cultures. *J Neurochem* **44**, 779-86 (1985).
- 914 56. Hosli, E. & Hosli, L. Autoradiographic localization of binding sites for vasoactive 915 intestinal peptide and angiotensin II on neurons and astrocytes of cultured rat central 916 nervous system. *Neuroscience* **31**, 463-70 (1989).
- 917 57. Delgado, M. & Ganea, D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. *Amino Acids* **45**, 25-39 (2013).
- 919 58. Baer, G.M. *et al.* Sporadic FTLD TDP type C is a distinct clinicopathological entity from FTLD types A/B (\$7.007). *Neurology* **88**, \$7.007 (2017).
- 921 59. Rohrer, J.D. *et al.* The heritability and genetics of frontotemporal lobar degeneration. *Neurology* **73**, 1451-6 (2009).
- 923 60. Snowden, J., Neary, D. & Mann, D. Frontotemporal lobar degeneration: clinical and pathological relationships. *Acta Neuropathol* **114**, 31-8 (2007).
- 925 61. Pan, L. *et al.* Transcription Factor RBPJL Is Able to Repress Notch Target Gene Expression but Is Non-Responsive to Notch Activation. *Cancers (Basel)* **13**(2021).

- 927 62. Bonham, L.W. *et al.* Genetic variation across RNA metabolism and cell death gene 928 networks is implicated in the semantic variant of primary progressive aphasia. *Sci Rep* 929 **9.** 10854 (2019).
- 930 63. Lu, J. *et al.* L3MBTL1 regulates ALS/FTD-associated proteotoxicity and quality control. *Nat Neurosci* **22**, 875-886 (2019).
- 932 64. Guissart, C. *et al.* Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay. *Sci* 934 *Rep* **10**, 20738 (2020).
- 935 65. Murley, A.G. & Rowe, J.B. Neurotransmitter deficits from frontotemporal lobar degeneration. *Brain* **141**, 1263-1285 (2018).
- 937 66. Ferrer, I. Neurons and their dendrites in frontotemporal dementia. *Dement Geriatr Cogn Disord* **10 Suppl 1**, 55-60 (1999).
- 939 67. Premi, E. *et al.* Unravelling neurotransmitters impairment in primary progressive aphasias. *Hum Brain Mapp* **44**, 2245-2253 (2023).
- 941 68. Bowen, D.M. *et al.* Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. *Psychopharmacology (Berl)* **196**, 603-10 (2008).
- 943 69. Procter, A.W., Qurne, M. & Francis, P.T. Neurochemical features of frontotemporal dementia. *Dement Geriatr Cogn Disord* **10 Suppl 1**, 80-4 (1999).
- 945 70. Premi, E. *et al.* Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study. *Neurobiol Dis* **179**, 106068 (2023).
- 947 71. Ghezzi, L., Cantoni, C., Rotondo, E. & Galimberti, D. The Gut Microbiome-Brain Crosstalk in Neurodegenerative Diseases. *Biomedicines* **10**(2022).
- 72. Khawar, M.M., Sr. *et al.* The Gut-Brain Axis in Autoimmune Diseases: Emerging
 Insights and Therapeutic Implications. *Cureus* 15, e48655 (2023).
- 951 73. Miller, Z.A. *et al.* TDP-43 frontotemporal lobar degeneration and autoimmune disease. *J Neurol Neurosurg Psychiatry* **84**, 956-62 (2013).
- 953 74. Olson, J.E. *et al.* The Mayo Clinic Biobank: a building block for individualized medicine. *Mayo Clin Proc* **88**, 952-62 (2013).
- 955 75. McPeek, M.S. & Sun, L. Statistical tests for detection of misspecified relationships by use of genome-screen data. *Am J Hum Genet* **66**, 1076-94 (2000).
- 957 76. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-1 (2010).
- Lake, B.B. *et al.* Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. *Nat Biotechnol* 36, 70-80 (2018).
- Allen, M. *et al.* Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. *Sci Data* **3**, 160089 (2016).
- 963 79. Mostafavi, S. *et al.* A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease. *Nat Neurosci* **21**, 811-819 (2018).
- 966 80. Bennett, D.A. *et al.* Religious Orders Study and Rush Memory and Aging Project. *J Alzheimers Dis* **64**, S161-S189 (2018).
- Wang, M. *et al.* The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease. *Sci Data* **5**, 180185 (2018).
- 970 82. Consortium, G.T. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318-1330 (2020).
- 972 83. Bryois, J. *et al.* Cell-type-specific cis-eQTLs in eight human brain cell types identify 973 novel risk genes for psychiatric and neurological disorders. *Nat Neurosci* **25**, 1104-974 1112 (2022).
- 975 84. Young, A.M.H. *et al.* A map of transcriptional heterogeneity and regulatory variation in human microglia. *Nat Genet* **53**, 861-868 (2021).

- 977 85. Lopes, K.P. *et al.* Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. *Nat Genet* **54**, 4-17 (2022).
- 979 86. Wingo, A.P. *et al.* Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. *Nat Genet* **53**, 143-981 146 (2021).
- 982 87. Ng, B. *et al.* An xQTL map integrates the genetic architecture of the human brain's transcriptome and epigenome. *Nat Neurosci* **20**, 1418-1426 (2017).
- 984 88. Alasoo, K. *et al.* Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. *Nat Genet* **50**, 424-431 (2018).
- 986 89. Nedelec, Y. *et al.* Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens. *Cell* **167**, 657-669 e21 (2016).
- 988 90. Chen, L. *et al.* Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells. *Cell* **167**, 1398-1414 e24 (2016).
- 990 91. Momozawa, Y. *et al.* IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. *Nat Commun* **9**, 2427 (2018).
- 992 92. Quach, H. *et al.* Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. *Cell* **167**, 643-656 e17 (2016).
- 994 93. Fairfax, B.P. *et al.* Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. *Science* **343**, 1246949 (2014).
- 996 94. Kerimov, N. *et al.* A compendium of uniformly processed human gene expression and splicing quantitative trait loci. *Nat Genet* **53**, 1290-1299 (2021).
- 998 95. Mancuso, N. *et al.* Probabilistic fine-mapping of transcriptome-wide association studies. *Nat Genet* **51**, 675-682 (2019).
- 1000 96. Ioannidis, N.M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* **99**, 877-885 (2016).

1006 **Declarations**

1002

1003

1004

1005

1007 Ethics approval and consent to participate

- This study was approved by the appropriate Mayo Clinic Institutional Review Board.
- 1009 Consent for publication
- 1010 Not applicable.

Competing interests

1011

1012

RR and IRM receive royalties from progranulin-related patent.

Funding 1013 1014 This work was made possible by the support of funding from the UG3/UH3 NS103870, P30 1015 AG062677, P01 AG003949, R01 AG037491, P01 NS084974, R01 AG37491, R01 DC12519, 1016 R21 NS94684, R01 DC010367, P30 AG062422, P01 AG019724, U01 AG057195, U19 1017 AG063911, P30 AG077444, P30 AG013854, P30 AG07297, P30 AG066468, P30 1018 AG012300, P30 AG072972, P30 AG010129, P50 AG005136, P30 AG066509, P30 1019 AG066511, P01 AG066597, P30 AG072979, R01 AG077444, and R01 DC008552. 1020 Supported by the ALLFTD Consortium (U19: AG063911, funded by the NIA and NINDS) and the former ARTFL & LEFFTDS Consortia (ARTFL: U54 NS092089, funded by the 1021 1022 NINDS and NCATS; LEFFTDS: U01 AG045390, funded by the NIA and NINDS). 1023 Supported by the Mayo ADRC (P30 AG62677, funded by the NIA). A subset of samples 1024 were obtained through the National Centralized Repository for Alzheimer Disease and 1025 Related Dementias (NCRAD), which receives government support under a cooperative 1026 agreement grant (U24 AG021886) awarded by the National Institute on Aging (NIA), were 1027 used in this study. The work was supported by Mayo Clinic Center for Regenerative 1028 Medicine, the gifts from the Donald G. and Jodi P. Heeringa Family, the Haworth Family 1029 Professorship in Neurodegenerative Diseases fund, The Albertson Parkinson's Research 1030 Foundation, and PPND Family Foundation. 1031 This work was supported by TARGET ALS, the Rainwater Charitable Foundation and the 1032 Bluefield Project to Cure FTD, the DEC Brain and BioBank, CIHR grant 74580, the 1033 Canadian Consortium on Neurodegeneration in Aging, of the Canadian Institutes of Health 1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

Research, the University of Pittsburgh Brain Institute. This work was supported by the NIHR UCL/H Biomedical Research Centre, the UK MRC (MR/M008525/1; MR/M023664/1), the Bluefield Project and the JPND (2019-02248). This work was made possible, in part, by the Winspear Family Center for Research on the Neuropathology of Alzheimer disease, the McCune Foundation, and the Nancy and Buster Alvord endowment. Research was supported by Grants provided by Swedish FTD Initiative- Schörling foundation, the Swedish research Council (Dnr 521-2010-3134, 529-2014-7504, 2015-02926), Alzheimer Foundation Sweden, Brain Foundation Sweden, Swedish Brain Power, Gamla Tjänarinnor, Stohnes Foundation, Dementia Foundation Sweden and the Stockholm County Council (ALFproject). The brain pathology was provided through in part by the Brain Bank at Karolinska Institutet which was financially supported by Karolinska Institutet StratNeuro, Swedish Brain Power, Stockholm County Council core facility funding (CG) and Schörling Foundation. This work was supported in part by SAO-FRA 2021/0032. FK receives a postdoctoral fellowship (BOF 49758) from the University of Antwerp Research Fund. **Acknowledgements** We thank the Mayo Clinic Center of Individualized Medicine for collection and sequencing of the Mayo Clinic Biobank samples. CG would also like to acknowledge Dr Inger Nennesmo for the neuropathological characterization. Acknowledgment for the ADSP dataset can be found in Supplementary Notes.

10561057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

Legends Figure 1: Genome-wide association study on common variants. A Manhattan plot of the FTLD-TDP All patients versus controls association study. **B** Manhattan plot of the FTLD-TDP A patients versus controls association study. C Manhattan plot of the FTLD-TDP B patients versus controls association study. **D** Manhattan plot of the FTLD-TDP C patients versus controls association study. The red-dotted line represents the genome-wide significance level $(p = 5x10^{-8}).$ Figure 2: Gene prioritization results for FTLD-TDP subgroups. A visual summary of weighted evidence category scores for the prioritized genes within genome-wide significant and subthreshold loci with candidate genes whose 1 Mb extended gene coordinates contain a minimal GWAS P evidence of $\leq 5 \times 10^{-6}$ in related FTLD subtype-specific GWAS summary statistics. Using the gene prioritization strategy in these selected loci, we prioritized a total of 25 genes in 23 loci at two different confidence levels (10 tier 1 and 15 tier 2 prioritized genes). The leftmost squares which are colored in red for FTLD-TDP A, in blue for FTLD-TDP B, and in green for FTLD-TDP C specific analyses indicate the locus index numbers which contain additional "S" patterns for the subthreshold loci, whereas others indicate the genome-wide significant loci. The types of evidence for each category are colored according to the six different domains to which they belong. Weighted scores for each evidence category are rescaled to a 0-100 scale based on the maximum score a candidate gene can obtain from a category (see Supplementary Table 2). The darker colors represent higher scores in categories, while tier 1 prioritized genes are displayed in dark green and tier 2 prioritized genes are displayed in light green. Only tier 1 and tier 2 genes are shown for each locus, and all candidate genes considered and scored can be found in **Supplementary Table 3**. MAFs (based on gnomAD v4 non-Finnish European samples) and CADD (v1.7) PHRED scores for rare and/or protein-altering rare variants are labeled in white within the respective squares. eQTL,

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

expression QTL; sQTL, splicing QTL; mQTL, methylation QTL; pQTL, protein-expression QTL; haQTL, histone acetylation QTL; coloc, colocalization; eTWAS, expression transcriptome-wide association study; sTWAS, splicing transcriptome-wide association study; PWAS, proteome-wide association study; Mon. Mac., monocytes and macrophages; LCL, lymphoblastoid cell line; QTLCat, The eQTL Catalogue. Figure 3: Top 5 Gene Ontology terms enriched in FTLD-TDP subgroups. Hierarchical GO analysis of biological process terms considering genes in genetic loci prioritized for FTLD-TDP All, FTLD-TDP A, FTLD-TDP B and FTD-TDP C. Figure 4: Enrichment of brain regions and cell types in FTLD subgroups. A Enrichment of genes in multiple tissues, including 13 brain regions, and based on GTEX data in FTLD subgroups, ADRD and ALS. Color represents the enrichment coefficient, and size indicates two-sided -log10 (FDR adjusted Ps) of enrichment obtained by the linear regression model in the MAGMA gene property analysis. **B** Central nervous system cell type enrichment analyses in FTLD subgroups, ADRD and ALS. Color represents the enrichment coefficient, and size indicates two-sided –log10 (FDR adjusted Ps) of enrichment obtained by the linear regression model in the MAGMA gene property analysis. Excitatory neurons and glial cells are highlighted in blue. Excitatory and inhibitory neurons from the PsychENCODE dataset were labeled based on their transcriptional profile from 1 to 8. Asterisks denote brain regions or cell types enriched with FDR P<0.05. Cx, cortex; Ex*, Excitatory neuron, In*, inhibitory neurons; Oligo, oligodendrocytes; OPCs, oligodendrocyte progenitor cells; Astro, astrocytes; Endo, endothelial cells; Per, pericytes. Figure 5: Locus zoom plots for *UNC13A* and *TNIP1* loci. A Genetic colocalization between the UNC13A locus in FTLD-TDP (meta-analysis) and ALS signal. **B** Genetic colocalization between the TNIP1 locus in FTLD-TDP (meta-analysis) and ALS. C Genetic colocalization between the *TNIP1* locus in FTLD-TDP (meta-analysis) and ADRD. For **A**, **B** and **C**, chromosome position is located on the x axis and $-\log 10(P)$ is represented on the y axis. Each dot represents a SNV tested in the dataset for its association with disease status. Purple diamonds are the index SNVs reported. Linkage disequilibrium with index SNV is indicated by r^2 .

Figure 6: Rare loss of function and predicted pathogenic variants in proteins associated with FTLD. Schematic representation of VIPR1, L3MBTL1 and RBPL protein structure (source Uniprot) showing a map of nonsense, splicing, frameshift and missense with a REVEL score>0.75 rare variants in patients and controls. Variants identified in patients are colored in orange, variants identified in controls are colored in blue. n=number of carriers.

Figure 7: Schematic representation of findings from the International FTLD-TDP WGS phase II. Genome-wide significant single variant loci, exome-wide significant genes, enriched gene ontology pathways and tissues- and cell-types enriched for genome-wide significant risk loci are shown for each FTLD-TDP pathological subtype in rings moving from the center (genome-wide significant single variant loci in FTLD-TDP All) to the outer rings. Orange background shades correspond to FTLD-TDP A findings, green background shades to FTLD-TDP B findings and blue background shades to FTLD-TDP C findings. Gene names in green font were exome-wide significant using a gene-based approach with common variants while gene names in red font were exome-wide significant using a gene-based approach with rare variants. In addition to unique associations, some overlap between FTLD-TDP A and B exist (TBK1, lysosomal function and inflammatory response), whereas FTLD-TDP C showed unique and non-overlapping genetic profile.

Table 1: Demographics after quality control.

	FTLD-TDP A	FTLD-TDP B	FTLD-TDP C	FTLD-TDP U ^a	Control
Number	193	288	467	37	3,153
(% Female)	(42.49)	(38.89)	(48.61)	(40.54)	(56.71)
Age at onset or age at collection (Standard Deviation, years)	68.00 (10.52)	62.00 (10.76)	60.50 (8.05)	60.50 (8.74)	64.08 (14.31)
Age at death (Standard Deviation, years)	78.00 (11.72)	67.00 (10.90)	72.00 (7.32)	67.84 (9.41)	82.00 (8.41)
Disease duration (Standard Deviation, years)	7.30 (4.65)	4.00 (3.61)	11.00 (7.46)	6.50 (5.20)	NA

^aFTLD-TDP U = FTLD-TDP unclassifiable

Table 2: Top variants associated with disease status

GROUP	rsID ^a	REF/ALT	LOCUS NAME ^b	GENOMIC POSITION ^c	ODDS RATIO (95% CI) ^d	P	MAF PATIENTS/CONTROLS	NEW LOCUS
FTLD-TDP All	rs8111424	A/G	UNC13A	19:17640336	1.37 (1.24-1.54)	1.17X10 ⁻⁸	0.376/0.141	
FTLD-TDP A	rs5848	C/T	GRN	17:44352876	1.89 (1.52-2.34)	5.57X10 ⁻⁹	0.442/0.292	New
FTLD-TDP A	rs138698596	T/A	TINAG	6:54591659	5.22 (2.91-9.36)	3.01X10 ⁻⁸	0.045/0.009	New
FTLD-TDP A	rs138959102	C/T	MZT1	13:72499532	8.41 (3.95-17.88)	3.22X10 ⁻⁸	0.029/0.004	New
FTLD-TDP A	rs886815	G/A	FARP2	2:241457011	9.55 (4.26-21.41)	4.26X10 ⁻⁸	0.026/0.003	New
FTLD-TDP B	rs76742217	G/A	RCL1	9:4821273	9.31 (4.30-20.18)	1.55X10 ⁻⁸	0.023/0.003	New
FTLD-TDP B	rs12973192	G/C	UNC13A	19:17642430	1.74 (1.46-2.08)	8.52X10 ⁻¹⁰	0.484/0.346	
FTLD-TDP B	rs527749954	C/T	PDS5B	13:32620689	7.66 (3.71-15.84)	3.89X10 ⁻⁸	0.025/0.003	New
FTLD-TDP B	rs871269	C/T	TNIP1	5:151052827	0.55 (0.44-0.68)	4.72X10 ⁻⁸	0.206/0.322	New
FTLD-TDP C	rs576561313	C/T	C19orf52	19:10945440	13.11 (5.33-32.23)	2.03X10 ⁻⁸	0.014/0.001	New

^ars number, according to dbSNP build 153.

^bNearest protein-coding gene according to GENCODE release 33.


^cGRCh38 assembly.

 $^{^{\}rm d}$ Approximate OR calculated with respect to the alternative allele.

Table 3: Genes harboring rare variants associated with FTLD-TDP

GROUP	GENE NAME	NUMBER OF PATIENTS	MAF ^a IN PATIENTS	NUMBER OF CONTROLS	MAF ^a IN CONTROLS	P
FTLD-TDP A	TBK1	3	7.77X10 ⁻⁰³	0	0	1.27X10 ⁻¹¹
FTLD-TDP B	TBK1	5	8.68X10 ⁻⁰³	0	0	3.17X10 ⁻¹²
FTLD-TDP B	VIPR1	3	5.21X10 ⁻⁰³	1	1.59X10 ⁻⁰⁴	4.65X10 ⁻⁷
FTLD-TDP C	RBPJL	5	5.35X10 ⁻⁰³	3	4.76X10 ⁻⁰⁴	6.39X10 ⁻⁷
FTLD-TDP C	L3MBTL1	8	8.57X10 ⁻⁰³	3	4.76X10 ⁻⁰⁴	2.38X10 ⁻⁷

^aMAF = minor allele frequency



Integration

Integration

Gene Tier

GO Terms across Groups



